Governance at a Glance

Chair
Member
Board Members Audit Compensation

Jack H. Dean, PhD, ScD (Hon), DABT, Fellow ATS

Robert J. DeLuccia

James Donohue

Thomas Harrison

David P. Luci, CPA, Esq.

Carl Sailer

Joseph C. Scodari

Jack H. Dean, PhD, ScD (Hon), DABT, Fellow ATS

From October 2010 until its sale in April 2017 to PLX Pharma, Inc. (Nasdaq: PLXP), Dr. Dean served as a director of Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development which was co-founded by our current co-founders in 2010. Since 2006, Dr. Dean has served as an advisor to the Executive Vice President of Drug Development for Sanofi, consulting on drug development strategy, drug safety issues and immunotoxicology through his company Drug Development Advisors, LLC where he serves as President. Dr. Dean is also a research professor in the departments of Medical Pharmacology and Pharmacology/ Toxicology, Colleges of Medicine and Pharmacy, at University of Arizona in Tucson. Prior to January 2006, Dr. Dean served as the President, U.S. Science and Medical Affairs (R&D), Sanofi in Malvern, Pennsylvania and the Global Director of Preclinical Development for Sanofi. Dr. Dean joined Sterling Winthrop in

1988, as Director of the Department of Toxicology and was appointed Vice President, Drug Safety worldwide in 1989. In addition, Dr. Dean served as Director of the Sterling Winthrop Research Center in Alnwick, England from 1990 to 1992. Dr. Dean was appointed Executive Vice President, Drug Development, in 1992 where he managed Non-Clinical and Clinical Development, and Regulatory Affairs. Before joining Sterling Winthrop, Dr. Dean headed the Department of Cellular and Molecular Toxicology, Chemical Industry Institute of Toxicology, Research Triangle Park, NC from 1982 to 1988. Prior to 1982, he headed the Immunotoxicology Section, National Institute of Environmental Health Services and National Toxicology Program, NIH in Research Triangle Park. From 1972 to 1979, Dr. Dean was in the Department of Immunology at Litton Bionetics (Department Director from 1975 to 1979) conducting research in tumor immunology. Dr. Dean holds a Bachelor of Science in microbiology and a Master of Science in medical microbiology from California State University at Long Beach. He earned a Ph.D. in molecular biology and minor in biochemistry in 1972 from the College of Medicine, University of Arizona. Dr. Dean held adjunct professorships at the University of North Carolina, Chapel Hill and Duke University from 1981 to 1988. Dr. Dean was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.

Robert J. DeLuccia

  • Former Executive Chairman of Dipexium, a pharmaceutical company focused on Ph3 clinical development of an antimicrobial peptide for diabetic foot infection.
  • Responsibilities included all CMC, pre-clinical/clinical and regulatory activities, including direct liaison to FDA on all regulatory matters for multiple product candidates.
  • Over 45 years executive experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Held senior executive positions in both companies and also CEO of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP).
  • Areas of experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (amifloxacin, doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: antiypertensive, heart failure, diagnostic contrast media, clopidogrel (antiplatelet agent).
  • Other: antianxiety/antidepression.
  • Topical new drug development areas include: creams/gels/liquids for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection/wound care.
  • Lead Director of Board of Directors of IBEX Pharmaceuticals, a publicly-traded (IBT-TSX), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use (Including Heparinase I for monitoring hemostasis in presence of anticoagulants). IBEX also manufactures arthritis assays, which are widely used in osteoarthritis research.
  • Mr. DeLuccia received his undergraduate and MBA degree from Iona College, N.Y..

James Donohue

Mr. Donohue has been a Vice President with Charles River Associates (Nasdaq: CRAI), a leading global consulting firm specializing in economic, financial, and management consulting services, since April 2004. Mr. Donohue has nearly 30 years of experience in valuation, damages, and forensic accounting. Mr. Donohue is a Certified Public Accountant (CPA) in Maryland and has a Bachelor of Science degree in Accountancy from Villanova University. He is also a Certified Valuation Analyst (CVA) and is Accredited in Business Valuation (ABV). Mr. Donohue was selected to serve on our board of directors because of his expertise in financial accounting.

Thomas Harrison

Since June 2016, Mr. Harrison has served as Chairman Emeritus of the Diversified Agency Services (“DAS”) division of Omnicom Group Inc. (NYSE:OMC), the world’s largest group of marketing services companies, having previously served as its President, then Chairman and CEO. DAS provides an unparalleled range of marketing communications services including public relations, crisis management, branding, sales promotion, customer relationship management and specialty communications including health care advertising. With over 5000 worldwide clients, the DAS division under Mr. Harrison had annual revenues of over $6.0 billion and became the largest business unit within Omnicom Group.

Under Mr. Harrison’s leadership, the DAS division grew from Omnicom’s smallest to its largest division and accounted for over 50% of Omnicom’s total revenues. He acquired and led a group of companies which became the most influential in their respective disciplines and built the largest, most innovative, diverse and relevant group of specialized agencies.

Mr. Harrison’s multi-faceted career brought him to Omnicom in 1992 when Omnicom acquired the firm he co-founded, Harrison & Star Business Group, which was the most successful and rapidly growing agency group in the healthcare industry. Mr. Harrison served as Chairman of the Harrison & Star Group and Chairman of Diversified Healthcare Communications, a group of eight healthcare agencies within Omnicom, until his appointment as President of DAS in 1997. He was named Chairman and Chief Executive of DAS in 1998 and remained in this role until being named Chairman Emeritus in 2013

With an advanced degree in cell biology and physiology, Mr. Harrison began his business career at Pfizer Laboratories as a pharmaceutical sales representative His agency, Harrison & Star, was an entrepreneurial agency that fused high science with high creativity. The agency became uniquely positioned in the market due to its understanding of the clinical and scientific underpinnings of prescription product promotion and its ability to communicate with practicing physicians using the language of science not sales.

Mr. Harrison brought his scientific acumen and career experience in healthcare, wellness, branding and communication to the evolving cannabis marketplace in 2015 when he joined the Board of Directors of Zynerba Pharmaceuticals, a leader in pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare psychiatric disorders. Mr. Harrison joined Merida Capital Partners in 2019 as Senior Operating Partner. At Merida, he serves as a strategic and operational advisor across the firm’s portfolio companies. Mr. Harrison is focused on contributing his expertise to this dynamic industry as it continues to unfold.

Mr. Harrison is a member of the Executive Committee of the Montefiore Health System and currently sits on the board of Fifth Street Asset Management (2014 – Present) where he serves as Lead Independent Director and Chairman of the Audit Committee. He also serves on the board of Madison Logic, a digital business to business agency (2017 – Present). Most recently, Mr. Harrison was appointed to the board of MainStem, a cannabis-related supply company and also ACTV8me, a digital advertising attribution company.

Mr. Harrison is a past board member at ePocrates, a publicly traded healthcare information company, where he served from 2006 until its acquisition in 2013 and he has also served as a board member for The Morgans Hotel Group (2006 – 2013). Mr. Harrison joined the board of Dipexium Pharmaceuticals in 2011 and served until its acquisition in 2017. He was a board member of rVue, a digital out-of-home media company from 2013 until 2016 and sat on the board of Social Growth Technologies from 2014 until its acquisition in 2016. Mr. Harrison was appointed to the board of directors of Zynerba Pharmaceuticals in 2015 serving as Chair of the Nominations and Corporate Governance Committee and as a member of the Compensation Committee until 2019 when he joined Merida Capital Partners.

Mr. Harrison earned an LH.D and Masters of Science in cell biology from West Virginia University, and a Bachelor of Science in cell biology and physiology from Shepherdstown University. Mr. Harrison was selected to serve on our board of directors because of his extensive public company experience and his knowledge of the pharmaceutical industry.

David P. Luci, CPA, Esq.

  • Former CEO of Dipexium, a pharmaceutical company focused on Ph3 clinical development of an antimicrobial peptide for diabetic foot infection.
  • Responsibilities include capital raising efforts, investor relations, public relations, corporate development, business development, legal and finance activities more than seven years as CEO of Dipexium Pharmaceuticals in the antimicrobial/wound care area (Nasdaq: DPRX) as well as more than five years at Bioenvision (Nasdaq: BIVN) serving in roles as CFO, General Counsel and Executive Vice President.
  • Raised over $180 million in equity financing as CEO or CFO of 4 public and 2 non-public pharmaceutical companies including approximately $70 million as CEO of Dipexium.
  • Obtained analyst coverage by 9 Wall Street brokerage firms (3 firms at Dipexium; 6 firms at Bioenvision), including JP Morgan, UBS, CIBC, FBR, Raymond James, Feltl & Co. and Oppenheimer. Dipexium experience included three “Buy” or Strong Buy” recommendations.
  • Led 4 public offerings, including two IPO’s with two Nasdaq listings) and two secondary offerings (one Amex listing) in addition to 10 to 12 private equity offerings.
  • Led three in-licensing or out-licensing opportunities; negotiated the sale of Bioenvision (Nasdaq: BIVN) to Genzyme for $345 million and merger of Dipexium with PLx Pharma ($69 million).
  • Currently serves as Chairman of the Board of Directors of Ameri Holdings Inc. (Nasdaq: AMRH). Previously served on the Board of Directors of Abeona Therapeutics (Nasdaq: ABEO), PLx Pharma Inc. (Nasdaq: PLXP) and Dipexium Pharmaceuticals (Nasdaq: DPRX). Member, Steering Committee for the worldwide development of a leukemia drug with two members from Genzyme.
  • Mr. Luci is a CPA in the State of Pennsylvania (Inactive) and a corporate lawyer and is a graduate with a Bachelor of Science in Business Administration (Accounting) from Bucknell University and a J.D. (Cum Laude) from Albany Law School of Union University.

Carl Sailer

Mr. Sailer’s career extends almost 30 years as a commercial leader in the biopharmaceutical industry. He is currently Senior Vice President, Global Client Solutions for Syneos Health, a fully integrated biopharmaceutical solutions company that is expertised in taking new therapies to market, from clinical stage through commercial stage.  Mr. Sailer leads global customer-centric commercial account teams for two of the company's leading large pharma clients. Prior to Syneos Health, Mr. Sailer served as the Vice President of Sales and Marketing for Emisphere Technologies (ultimately acquired by Novo Nordisk), Vice President of Commercial Operations at New American Therapeutics (ultimately acquired by Renaissance Pharma) and Akrimax Pharmaceuticals, in each case, where he built and led the commercial organizations for each start-up company.

Previously, Mr. Sailer was a member of the Executive Committee at PDI, a leading contract commercial organization, where he held several leadership positions in product commercialization and business development. Mr. Sailer started his career by holding various sales, marketing and sales management roles in the pharmaceutical and consumer products divisions of Bristol-Myers Squibb and Bayer Healthcare.

Mr. Sailer earned an MBA from Hofstra University, and a BS in marketing with a minor in journalism from Seton Hall University, where he has been an adjunct graduate school professor and currently serves on the Advisory Board of the Market Research Center at the Stillman School of Business.

Joseph C. Scodari

Since October 2017, Mr. Scodari has served as Chairman of the Board of Directors of Optinose (NASDQ:OPTN), a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (“ENT”) and allergy specialists. Mr. Scodari was previously Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson’s Executive Committee from March 2005 until his retirement in March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson’s Biopharmaceutical Business. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998, a position that he served in until Conocor Inc.’s acquisition by Johnson & Johnson in 1999. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug.

He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the Imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhône-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (“BIO”), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University. Mr. Scodari was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.